Upgrade to SI Premium - Free Trial

Jazz Pharmaceuticals (JAZZ) PT Raised to $307 at BofA Securities

June 10, 2026 5:22 AM
BofA Securities analyst Jason Gerberry raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $307.00 (from $281.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change